Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03)

Publication | Closed Access

DOI

Citations

References

2012

Year

Aristotelis Bamias, Urania Dafni, Alexandra Karadimou, Eleni Timotheadou, Gerasimos Aravantinos, Amanda Psyrri, Ioannis Xanthakis, Marinos Tsiatas, Vassilis Koutoulidis, C. Constantinidis,

Annals of Oncology

Surgical OncologyUrologyHe 16/03Genitourinary CancerMedicineRelapsed Urothelial CancerIii StudyCancer TreatmentOncologyRadiation Oncology